Investigating the Role of Genetics in Disease Predisposition
NCT06584994
Cancer, Disease Attributes
Cambridge, United Kingdom
View Trial DetailsNCT Number: NCT04419896
This prospective and retrospective registry will evaluate the clinical effectiveness of Germline Genetic, Genomic, and other Biomarker testing results over time in different clinical populations, in order to shape guidelines for testing, patient management, and precision therapy.
Interested in participating?
Request Info18 year and older
All sexes
Observational
North Valley Breast Clinic, Redding, California, United States
Interest and knowledge about the genetics and biology of an individual's inherited risk of disease and progression of disease is growing. Physicians are increasing using tests and technology, including Germline Genetic, Genomic, and Biomarker Testing, to provide insight into a healthy individual's risk and an affected individual's disease characteristics, in order to provide individualized clinical treatments. However, many barriers to widespread and appropriate Germline Genetic, Genomic, and Biomarker Testing persist due to complex guidelines for use, varied quality and cost, rapid advances, and adequate understanding of appropriate implementation by medical professionals. The iGAP Registry is a multi-center ongoing database designed to capture information on disease risk assessment, Germline Genetic, Genomic, and Biomarker Testing, and their utilization and impact on treatment practices and outcomes to help determine, over time, the most effective use of testing in varied patient populations and to support the increased use of precision medicine.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Retrospective Subjects:
Inclusion criteria
for Prospective Subjects:
Time frame: 10 years
To understand the utilization of Germline Genetic, Genomic, and Biomarker Testing in various clinical settings. The registry will gather information on patient demographics and personal and family history, as well as test results of Germline Genetic, Genomic, and Biomarker tests.
Time frame: 10 years
To understand Physician Decision Impact and Patient Reported Outcomes resulting from the utilization of Germline Genetic, Genomic, and Biomarker testing. This registry will gather information to capture the clinical management decision making processes of the physicians, before and after receiving information from Germline Genetic, Genomic, or other Biomarker testing. Further, this registry will collect information on Patient Reported Outcomes, or patient described impacts of Germline Genetic, Genomic, or other Biomarker testing on their treatment, clinician interactions, follow-up, and mental health.
Medneon
Industry
The Informed Genetics Annotated Patient Registry: The iGAP Registry
Acronym: iGAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06584994
Cancer, Disease Attributes
Cambridge, United Kingdom
View Trial DetailsNCT06450171
Cancer Predisposition Syndrome, Disease Attributes
Boston, Massachusetts, United States
View Trial DetailsNCT04848142
Disease Attributes, Disease Susceptibility
Memphis, Tennessee, United States
View Trial DetailsNCT03982446
Digestive System Diseases, Digestive System Neoplasms
Athens, Greece
View Trial Details